undamentalytics Newsletter
Sign in

Orchestra Biomed Holdings, Inc. (OBIO) stock

Add to watchlist

Add holding +

NASDAQ: OBIO Nasdaq Health Care Equipment Next results ~November 5, 2026

D Fundamentals grade

Orchestra Biomed Holdings, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.2

Growth cash-flow model

Base case. Range ~$1.2–$1.2. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Orchestra Biomed Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 2 selling9 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds47 adding, 28 cuttingOf 16 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Orchestra Biomed Holdings files

Where Orchestra Biomed stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $32m, up 986.1% on a year earlier, slower than the 1033.9% growth a quarter earlier. That growth ranks 2 of 103 among the health care equipment companies we cover. Free-cash-flow margin rose to -184.8% from -2027.9% a year earlier. Operating margin widened to -181.4% from -2420.8%. The diluted share count is up 58.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 4 of our 6 financial-health checks.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Orchestra Biomed Holdings, Inc.'s trailing-twelve-month revenue grew 986.1% year on year, with a free-cash-flow margin of -184.8%. Where it stands out: gross margin of 99.5% ranks 1 of 123 health care equipment companies we cover. Where it lags: change in growth rate of -47.7pp ranks 126 of 129 health care equipment companies we cover.

Current signal Gross margin expanding: TTM gross margin reached 99.5%, up 6.8pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 986.1% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 2239.4 points on a year ago.

Things to watch

  • Growth slowing. The growth rate is 47.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -181.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -184.8% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 34.8% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 58.1% in a year.
  • High sales multiple. The shares trade at 11 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.37 against an average estimate of -$0.37: beat by 0.1%
Revenue
$0m, down 89.5% on a year earlier
Next report
November 5, 2026; average EPS estimate -$0.40

Orchestra Biomed Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.7%
  • 1 week+2.5%
  • 1 month-4.4%
  • This year+37.1%
  • 1 year+45.9%
  • 5 years-42.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$32M
Operating margin
-181.4%
Net margin
-184.6%
EPS (TTM, diluted)
$-0.98

Growth

Revenue growth
+986.1%
Change in growth rate
−47.7 pts
Share count change
+58.1%

Cash

Free cash flow (TTM)
-$59.1M
FCF margin
-184.8%
Stock pay % of revenue
34.8%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Orchestra Biomed Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Orchestra Biomed Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.25 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.2 ~$1.2–$1.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.0 ~$0.0–$0.1 Left out: out of range vs price (0.00x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.2 ~$1.2–$1.2 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Orchestra Biomed Holdings, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$9.98$9.13$4.00$4.15$5.69
Market value$150m$303m$147m$198m$343m
+ Net debt (− = net cash)−$20m−$21m−$7m−$20m−$30000
Enterprise value$130m$283m$140m$178m$343m
Multiples
Price / sales 42.3x109.9x55.8x5.9x10.7x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $103500 and EPS of −$0.40 (range −$0.45 to −$0.37) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.52 −37% $451140 −99%
Next −$1.51 +0% $600140 +33%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.4% on 90 days ago. In the last 30 days, 2 analysts raised Orchestra Biomed Holdings, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Orchestra Biomed Holdings, Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.50 Current fiscal year, 60 days ago: −$1.52 Current fiscal year, 30 days ago: −$1.52 Current fiscal year, 7 days ago: −$1.52 Current fiscal year, Now: −$1.52 −$1.52 Next fiscal year, 90 days ago: −$1.46 Next fiscal year, 60 days ago: −$1.52 Next fiscal year, 30 days ago: −$1.51 Next fiscal year, 7 days ago: −$1.51 Next fiscal year, Now: −$1.51 −$1.51

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.50−$1.46
60 days ago −$1.52−$1.52
30 days ago −$1.52−$1.51
7 days ago −$1.52−$1.51
Now −$1.52−$1.51

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.37 −$0.37 +0.1%
Dec 2025 −$0.38 $0.26 +168.7%
Sept 2025 −$0.43 −$0.40 +6.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026167
  2. Sep 2026167
  3. Aug 20261517
  4. Jul 20261517

Counts of recommendations published by analysts covering Orchestra Biomed Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.9%
of tradable shares
Days to cover
8.11
at average volume
Short interest, 1 month
+8%
to October 15, 2026
Held by institutions
48%
of shares
Held by insiders
24.4%
of shares
Employees
86
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OBIO−21%−1%−9%−56%+4%+37%
Industry peers (median)−7%−37%−9%−19%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OBIO33%67%50%33%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OBIO−33%−3%−80%−58%−61%−28%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 4, 2020: 89% from April 12, 2023 to September 23, 2025. Getting back needed a 844% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.49 – $6.35
From 52-week high
−10.4%
vs 50-day average
−0.3%
vs 200-day average
+25.3%
Volatility (1 year)
64%
Beta vs S&P 500
1.58

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Orchestra Biomed Holdings, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Orchestra Biomed Holdings, Inc.
$0 $10M $20M $30M $40M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.6M Revenue (TTM), FY23 Q4: $2.8M Revenue (TTM), FY24 Q1: $2.2M Revenue (TTM), FY24 Q2: $2.1M Revenue (TTM), FY24 Q3: $2.6M Revenue (TTM), FY24 Q4: $2.6M Revenue (TTM), FY25 Q1: $2.9M Revenue (TTM), FY25 Q2: $2.9M Revenue (TTM), FY25 Q3: $2.8M Revenue (TTM), FY25 Q4: $33.5M Revenue (TTM), FY26 Q1: $32.7M Revenue (TTM), FY26 Q2: $32M $32M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.6M
FY23 Q4 $2.8M
FY24 Q1 $2.2M
FY24 Q2 $2.1M
FY24 Q3 $2.6M
FY24 Q4 $2.6M
FY25 Q1 $2.9M
FY25 Q2 $2.9M
FY25 Q3 $2.8M
FY25 Q4 $33.5M
FY26 Q1 $32.7M
FY26 Q2 $32M
Revenue growth, TTM YoY Orchestra Biomed Holdings, Inc.
-500% 0% 500% 1000% 1500% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q4: -21.9% Revenue growth, TTM YoY, FY24 Q1: -42.2% Revenue growth, TTM YoY, FY24 Q2: -52.2% Revenue growth, TTM YoY, FY24 Q3: -26.5% Revenue growth, TTM YoY, FY24 Q4: -4.4% Revenue growth, TTM YoY, FY25 Q1: 30.2% Revenue growth, TTM YoY, FY25 Q2: 41.6% Revenue growth, TTM YoY, FY25 Q3: 6.5% Revenue growth, TTM YoY, FY25 Q4: 1169.2% Revenue growth, TTM YoY, FY26 Q1: 1033.9% Revenue growth, TTM YoY, FY26 Q2: 986.1% 986.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -21.9%
FY24 Q1 -42.2%
FY24 Q2 -52.2%
FY24 Q3 -26.5%
FY24 Q4 -4.4%
FY25 Q1 30.2%
FY25 Q2 41.6%
FY25 Q3 6.5%
FY25 Q4 1169.2%
FY26 Q1 1033.9%
FY26 Q2 986.1%
Operating margin (TTM) Orchestra Biomed Holdings, Inc.
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1356.7% Operating margin (TTM), FY23 Q4: -1866.2% Operating margin (TTM), FY24 Q1: -2454.2% Operating margin (TTM), FY24 Q2: -2803.6% Operating margin (TTM), FY24 Q3: -2270.7% Operating margin (TTM), FY24 Q4: -2437.5% Operating margin (TTM), FY25 Q1: -2383.9% Operating margin (TTM), FY25 Q2: -2420.8% Operating margin (TTM), FY25 Q3: -2669.9% Operating margin (TTM), FY25 Q4: -154.7% Operating margin (TTM), FY26 Q1: -168.0% Operating margin (TTM), FY26 Q2: -181.4% -181.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1356.7%
FY23 Q4 -1866.2%
FY24 Q1 -2454.2%
FY24 Q2 -2803.6%
FY24 Q3 -2270.7%
FY24 Q4 -2437.5%
FY25 Q1 -2383.9%
FY25 Q2 -2420.8%
FY25 Q3 -2669.9%
FY25 Q4 -154.7%
FY26 Q1 -168.0%
FY26 Q2 -181.4%
FCF margin (TTM) Orchestra Biomed Holdings, Inc.
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1222.8% FCF margin (TTM), FY23 Q4: -1674.1% FCF margin (TTM), FY24 Q1: -2026.7% FCF margin (TTM), FY24 Q2: -2150.4% FCF margin (TTM), FY24 Q3: -1819.9% FCF margin (TTM), FY24 Q4: -1927.5% FCF margin (TTM), FY25 Q1: -1886.8% FCF margin (TTM), FY25 Q2: -2027.9% FCF margin (TTM), FY25 Q3: -2157.3% FCF margin (TTM), FY25 Q4: -147.7% FCF margin (TTM), FY26 Q1: -168.3% FCF margin (TTM), FY26 Q2: -184.8% -184.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1222.8%
FY23 Q4 -1674.1%
FY24 Q1 -2026.7%
FY24 Q2 -2150.4%
FY24 Q3 -1819.9%
FY24 Q4 -1927.5%
FY25 Q1 -1886.8%
FY25 Q2 -2027.9%
FY25 Q3 -2157.3%
FY25 Q4 -147.7%
FY26 Q1 -168.3%
FY26 Q2 -184.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 4 3 3 33 32
Gross profit 3 3 2 33 32
EBITDA −32 −51 −64 −51 −58
Operating income −33 −52 −64 −52 −58
Net income −34 −49 −61 −53 −59
Diluted EPS −$2.24 −$1.48 −$1.66 −$1.11 −$0.98
Growth (year on year)
Revenue — −21.9% −4.4% +>999% +986.1%
Margins
Gross margin 94.0% 93.3% 92.3% 99.4% 99.5%
EBITDA margin −918.1% <−999% <−999% −153.8% −180.3%
Operating margin −924.3% <−999% <−999% −154.7% −181.4%
Net margin −951.3% <−999% <−999% −157.4% −184.6%
Free-cash-flow margin −845.7% <−999% <−999% −147.7% −184.8%
Cash flow
Cash from operations −29 −46 −51 −49 −58
Capital spending 1 0 0 0 1
Free cash flow −30 −46 −51 −49 −59
Stock-based pay 3 8 11 12 11
Free cash flow after stock pay −33 −54 −61 −61 −70
Balance sheet
Cash 20 31 22 35 20
Total debt 0 10 15 15 20
Net debt (negative = net cash) −20 −21 −7 −20 −0
Diluted shares 15m 33m 37m 48m 60m
Returned to shareholders
Dividends 20 — — — —
Total returned 20 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $116m
Short-term assets $111mLonger-term assets $4m
What it owes, and who funded it · $106m
Short-term liabilities $13mLonger-term liabilities $73mShareholders' equity $19m
  • Short-term assets cover short-term liabilities $111m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $111m short-term assets against $73m of longer-dated liabilities.
  • More cash than debt $20m of cash against $20m of debt.
  • Debt below 40% of shareholders' equity Debt is 106% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$58m of operating cash flow against $20m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Orchestra Biomed Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+58.1%
year over year
R&D spending
197.7%
of revenue
Sales & admin spending
83.2%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated OBIO POCI RVP STXS UTMD ECOR Median
Revenue, last 12 months $32m $32m $34m $30m $36m $37m $99m
Revenue growth, last 12 months 986.1% 65.2% −11.2% −5.5% −7.0% 33.5% 9.2%
Revenue growth, 3-year average 94.5% 14.4% −14.7% 0.8% −11.4% 50.4% 13.5%
Revenue growth, latest quarter −89.5% 42.0% −31.1% −12.8% −14.3% 28.0% 10.2%
Gross margin 99.5% 17.2% −1.4% 55.6% 57.9% 87.1% 61.2%
Operating margin −181.4% −11.1% −66.9% −75.7% 28.4% −37.6% −8.5%
Operating margin, 3-year average <−999% −18.2% −52.5% −80.7% 31.2% −51.0% −17.9%
Net margin −184.6% −11.5% −9.9% −74.2% 29.0% −40.0% −12.0%
Cash from operations / revenue −182.4% −4.9% −14.6% −50.9% 32.8% −26.3% −1.9%
Free-cash-flow margin −184.8% −5.8% −37.7% −51.6% 31.7% −26.4% −3.9%
Free-cash-flow margin, 3-year average <−999% −13.4% −20.6% −37.3% 35.4% <−999% −7.0%
Stock pay / revenue 34.8% 3.5% 10.7% 28.8% 1.1% 7.2% 6.1%
Change in share count 58.1% 25.6% 0.0% 11.1% −4.8% 8.5% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 986.1% 9.1% 2 of 129
Change in growth rate Growth -47.7pp -0.6pp 126 of 129
Gross margin Profitability 99.5% 61.9% 1 of 123
Operating margin Profitability -181.4% -8.3% 108 of 132
Net margin Profitability -184.6% -12.0% 109 of 133
Free-cash-flow margin Cash generation -184.8% -3.4% 108 of 128
Stock pay as % of revenue Cash generation 34.8% 6.1% 107 of 123
Long-term debt as % of assets Balance sheet 17.7% 24.2% 35 of 87
Change in share count Balance sheet 58.1% 3.3% 107 of 115

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Partnership Revenue $32.9M 98.2% ▲ 1539.5%
Products $611,000 1.8% ▼ 3.5%

From Orchestra Biomed Holdings, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$119M
Institutions reporting
77
Shares held vs prior quarter
▲ 19.9%
Positions opened / closed
25 / 13

Top buyers and sellers, Q2 2026: 47 institutions bought and 28 sold ; the biggest buyer was Blackrock, Inc (+1.9M shares) and the biggest seller Millennium Management LLC (−703K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RTW Investments, LP $41.2M 9.6M 34.5% ▲ 15.0%
Perceptive Advisors LLC $21.7M 5.0M 18.2% 0.0%
Blackrock, Inc. $10.8M 2.5M 9.1% ▲ 294.9%
Vanguard Capital Management LLC $8.7M 2.0M 7.3% ▼ 8.2%
Geode Capital Management, LLC $4.4M 1.0M 3.6% ▲ 107.6%
Alyeska Investment Group, L.P. $4.3M 1.0M 3.6% 0.0%
Propel Bio Management, LLC $3.9M 897K 3.2% 0.0%
UBS Am, A Distinct Business Unit Of UBS Asset Management Americas LLC $2.8M 642K 2.3% New
State Street Corp $2.2M 516K 1.9% ▲ 204.6%
Rice Hall James & Associates, LLC $1.8M 424K 1.5% ▲ 2131.5%
Charles Schwab Investment Management Inc $1.5M 350K 1.3% ▲ 31.7%
Northern Trust Corp $1.5M 344K 1.2% ▲ 190.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Orchestra Biomed Holdings, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $279,891 9 trades by 4 insiders, last 12 months Insider sales History → $353,082 6 trades by 2 insiders · 100% under pre-set plans
Net ▼ $73,191 net selling
Insider Date Trade Shares Price Value
Sherman Darren See Remarks October 1, 2026 Sell pre-set plan 15,000 $6.36 $95,400
Hochman David P See Remarks September 3, 2026 Buy 10,000 $4.79 $47,900
Sherman Darren See Remarks September 1, 2026 Sell pre-set plan 15,000 $4.94 $74,100
Sherman Darren See Remarks August 26, 2026 Buy 2,000 $5.33 $10,660
Sherman Darren See Remarks August 3, 2026 Sell pre-set plan 15,000 $4.09 $61,350
Sherman Darren See Remarks July 1, 2026 Sell pre-set plan 15,000 $4.27 $64,050
Sherman Darren See Remarks June 1, 2026 Sell pre-set plan 15,000 $3.87 $58,050
Hochman David P See Remarks June 1, 2026 Buy 5,000 $3.83 $19,150
Aryeh Jason Director May 18, 2026 Buy 665 $3.75 $2,494
Hochman David P See Remarks May 15, 2026 Buy 5,000 $3.77 $18,850
Aryeh Jason Director May 15, 2026 Buy 8,971 $3.90 $34,987
Fain Eric S Director May 14, 2026 Buy 20,000 $4.13 $82,600

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Orchestra Biomed Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Orchestra Biomed Holdings, Inc. in brief

What does Orchestra Biomed Holdings, Inc. do?
Orchestra Biomed Holdings, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Orchestra Biomed Holdings, Inc.'s stock ticker?
Orchestra Biomed Holdings, Inc. trades under the ticker OBIO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Orchestra Biomed Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Orchestra Biomed Holdings, Inc. reported revenue of $32M, 986.1% higher than a year earlier, according to its SEC filings.
What is Orchestra Biomed Holdings, Inc.'s free cash flow?
Orchestra Biomed Holdings, Inc.'s free-cash-flow margin is -184.8% of revenue over the trailing twelve months, ranking 108 of the 128 health care equipment companies we cover.
Who are Orchestra Biomed Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RTW Investments, LP, Perceptive Advisors LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Orchestra Biomed Holdings, Inc.'s market cap?
On November 2, 2026, Orchestra Biomed Holdings, Inc.'s market capitalisation was about $343M and net debt of -$30,000. Market figures come from third-party market data and may be delayed.
How much debt does Orchestra Biomed Holdings, Inc. have?
Orchestra Biomed Holdings, Inc.'s debt-to-equity ratio is 105.8%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Orchestra Biomed Holdings, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Orchestra Biomed Holdings, Inc. are Precision Optics Corporation, Inc., Retractable Technologies Inc, Stereotaxis, Inc., Utah Medical Products Inc and Electrocore, Inc. The side-by-side comparison below sets their revenue, margins and growth against Orchestra Biomed Holdings, Inc.'s.
Are insiders buying or selling Orchestra Biomed Holdings, Inc. stock?
Over the last 12 months, Orchestra Biomed Holdings, Inc.'s directors and officers reported 9 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is Orchestra Biomed Holdings, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Orchestra Biomed Holdings, Inc. announces its own schedule.